文献速递淋巴瘤

维布妥昔单抗联合纳武利尤单抗及化疗治疗非巨块型早期经典霍奇金淋巴瘤

Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma.
PubMed 文献 · Blood · 2026-01-01

这项2期研究评估了AN+AD方案(维布妥昔单抗、纳武利尤单抗联合多柔比星和达卡巴嗪)治疗非巨块型早期经典霍奇金淋巴瘤的疗效与安全性。154例患者接受4周期AN+AD,治疗结束客观缓解率96%,完全缓解率92%,中位随访27.9个月时2年无进展生存率97%。结果表明该方案联合有限化疗支持用于此类患者。

要点

  • 非巨块型早期cHL患者接受4周期AN+AD,完全缓解率达92%。
  • 中位随访27.9个月,估计2年无进展生存率为97%。
  • ≥3级治疗相关不良事件发生率44%,未报告发热性中性粒细胞减少。

核心结论

  • AN+AD方案在非巨块型早期经典霍奇金淋巴瘤中显示出高完全缓解率和2年无进展生存率,支持其联合有限化疗的应用。

研究设计与样本

  • 这项2期研究纳入非巨块型(<10 cm)Ann Arbor I或II期经典霍奇金淋巴瘤患者,接受4周期AN+AD(维布妥昔单抗、纳武利尤单抗联合多柔比星和达卡巴嗪)。
  • 154例患者接受了至少1剂AN+AD治疗,主要终点为研究者评估的治疗结束时完全缓解率。

主要发现

  • 治疗结束时客观缓解率为96%(95%CI 91.7-98.6),完全缓解率为92%(95%CI 86.0-95.4)。
  • 预后良好亚组(n=56)和预后不良亚组(n=97)的完全缓解率分别为95%(95%CI 85.1-98.9)和91%(95%CI 83.1-95.7)。
  • 完全缓解持续时间至少2年的患者比例为96%(95%CI 90.9-98.4)。
  • 中位随访27.9个月时,估计2年无进展生存率为97%(95%CI 92.0-98.8)。
  • 任何级别和≥3级治疗中出现的不良事件发生率分别为99%和44%,未报告发热性中性粒细胞减少事件;任何级别治疗中出现的免疫介导不良事件发生率为22%。

关键数值与推荐

  • 非巨块型定义为<10 cm。
  • 治疗方案为4周期AN+AD。
  • 主要终点为治疗结束时研究者评估的完全缓解率。

临床怎么用

  • 对于非巨块型早期经典霍奇金淋巴瘤患者,可考虑采用维布妥昔单抗和纳武利尤单抗联合有限化疗(多柔比星和达卡巴嗪)的方案。

局限性

  • 安全性报告期后报告了1例疾病相关死亡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Most patients with early-stage classical Hodgkin lymphoma (cHL) are treated with doxorubicin, bleomycin, vinblastine, and dacarbazine with or without radiation therapy, although studies are now evaluating the incorporation of novel agents paired with abbreviated chemotherapy. We present the efficacy and safety of AN+AD (brentuximab vedotin [BV] and nivolumab in combination with doxorubicin and dacarbazine) in patients with early-stage cHL. In this phase 2 study, patients with nonbulky (<10 cm) Ann Arbor stage I or II cHL received 4 cycles of AN+AD. The primary end point was complete response (CR) rate at end of treatment (EOT) by investigator. At the time of this analysis, 154 patients received ≥1 dose of AN+AD. The objective response rate at EOT was 96% (95% confidence interval [CI], 91.7-98.6), and the CR rate was 92% (95% CI, 86.0-95.4). In the favorable (n = 56) and unfavorable (n = 97) subgroups, CR rates were 95% (95% CI, 85.1-98.9) and 91% (95% CI, 83.1-95.7), respectively. The proportion of patients with duration of CR of at least 2 years was 96% (95% CI, 90.9-98.4). At a median follow-up of 27.9 months, the estimated 2-year progression-free survival rate was 97% (95% CI, 92.0-98.8). Any-grade and grade ≥3 treatment-emergent adverse events occurred in 99% and 44% of patients, respectively; no events of febrile neutropenia were reported. Any-grade treatment-emergent immune-mediated adverse events occurred in 22% of patients. One disease-related death was reported after the safety reporting period. Results from this study support the use of BV and nivolumab in combination with limited chemotherapy for patients with nonbulky, early-stage cHL. This trial was registered at www.clinicaltrials.gov as NCT03646123.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Abramson JS, Straus DJ, Bartlett NL, et al. Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma. Blood. 2026. PMID: 41460964. doi:10.1182/blood.2025030190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。